Group 1 - Company Gilead Sciences-B (01672.HK) announced a placement and subscription agreement involving the sale of 52.4 million shares at a price of HKD 16.45 per share, which represents a discount of approximately 9.9% compared to the closing price of HKD 18.26 on August 18 [1] - The total number of shares being placed represents about 5.44% of the company's issued share capital, while the subscription of 28.82 million shares accounts for approximately 2.90% of the enlarged issued share capital [1] - Following the completion of the placement and subscription, the controlling shareholder's stake will decrease from approximately 62.21% to about 58.03% of the issued share capital [2] Group 2 - The total expected proceeds from the subscription amount to approximately HKD 474 million, with a net amount of about HKD 468 million after deducting commissions and estimated expenses [2] - Approximately 90% of the net proceeds from the subscription are intended for clinical trial development related to subcutaneous and oral peptide candidates for obesity, while about 10% is suggested for working capital and other general corporate purposes [2]
歌礼制药-B(01672.HK)拟折价配股募资4.7亿港元 加码肥胖症药物研发